Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 5/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29840428 | 1.00 | BRD4 (0.40) | BRD4BTKAKT1KCNQ3KCNQ2 | |
| SCHEMBL23304194 | 0.88 | BTK (0.37) | BTKKCNQ3KCNQ2NR3C1PGR | |
| SCHEMBL29840382 | 0.87 | BRD4 (0.42) | BRD4BTKAKT1KCNQ3KCNQ2 | |
| SCHEMBL23336440 | 0.87 | BRD4 (0.42) | BRD4BTKAKT1KCNQ3KCNQ2 | |
| SCHEMBL21425585 | 0.83 | BRD4 (0.42) | BRD4 | |
| SCHEMBL22664600 | 0.80 | STK17B (0.41) | BTKAAK1TRPV1PRMT5WDR77 | |
| SCHEMBL29533368 | 0.80 | STK17B (0.41) | BTKAAK1TRPV1PRMT5WDR77 | |
| SCHEMBL25575025 | 0.77 | BRD4 (0.42) | BRD4BTKAKT1TRPV1NSD2 | |
| SCHEMBL23337481 | 0.76 | PCSK9 (0.39) | BRD4BTKAKT1PRMT5WDR77 | |
| SCHEMBL29840373 | 0.76 | PCSK9 (0.39) | BRD4BTKAKT1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, CDK1, CDK2 | BRD4 113/4885BTK 4/4885AKT1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.